News and features

The discovery of a pathway that helps stem cells grow into different types of breast tissue could lead to new treatments for aggressive breast cancer.

Combining two different targeted therapies could greatly increase the effectiveness of bladder cancer treatments by blocking a tumour’s path to drug resistance, a new study reports.

Postgraduate degrees have been awarded to over 80 students, while honours were received by Professor Dame Janet Husband, Professor Sir Mike Stratton and The Honourable Thomas Henderson for their contributions to cancer research.

A new treatment for advanced prostate cancer that homes in on tumours has shown significant patient benefit in clinical trials, say ICR researchers.

The roots of the modern-day study of cancer risk lie all the way back in the nineteenth century at a nunnery in Italy. It was here in 1842 that a doctor called Rigoni-Stern noticed that nuns virtually never suffered from cervical cancer but had a higher than usual incidence of breast cancer, and wondered whether the explanation might lie in the nuns’ celibacy.

Read the ICR response to the Academy of Medical Sciences report, which makes recommendations to remove barriers to the development and adoption of stratified medicine.

A new combined treatment using the measles virus to target cancer could greatly improve bowel and head & neck cancer treatment, say ICR researchers

A new, targeted approach to radiotherapy could improve treatment of lung cancer by tracking a tumour’s movements as patients breathe in and out.

An over-active gene called GNAS may help drive the growth of some types of difficult-to-treat breast cancers, ICR scientists have found.

Over the last decade, advances in technology have triggered an explosion in our knowledge about the biology of adult cancers – but we know far less about what causes cancers in children.

The Institute of Cancer Research, London, has successfully retained its status as one of the UK’s specialist centres for designing and running clinical trials.

Scientists hope to reverse resistance that can develop to the next-generation prostate cancer treatment abiraterone by combining it with a promising experimental treatment, and believe the combination also has potential when given at an earlier stage to prevent resistance developing.